# US 7,745,493 B2 · Methods of treating tardive dyskinesia and other movement disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,493 B2
- Document ID: US7745493B2
- Status: Granted
- Kind: B2
- Application number: 11/340,802
- Filed: 2006-01-25
- Published: 2006-06-15
- Granted: 2010-06-29
- Earliest claimed: 1998-01-13
- Assignees: Synchroneuron, LLC
- Inventors: Barry S. Fogel
- Web page: https://patentgrep.com/patent/US7745493B2

## CPC

- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

## Claims

### Claim 1

A method for treating hyperkinesia comprising administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein said step of administering comprises oral administration.

### Claim 3

A method of treating a hyperkinetic movement disorder comprising the step of administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.

### Claim 4 (depends on 3)

The method of claim 3, wherein the hyperkinetic movement disorder is tardive dyskinesia or comprises involuntary movements similar to those seen in said tardive dyskinesia.

### Claim 5 (depends on 3)

The method of claim 3, wherein said movement disorder is the peak-dose dyskinesia in a patient with Parkinson's disease.

### Claim 6 (depends on 3)

The method of claim 3, wherein said movement disorder is associated with Huntington's disease.

### Claim 7 (depends on 3)

The method of claim 3, wherein said movement disorder is related to a deficiency in GABA in the basal ganglia.

### Claim 8 (depends on 3)

The method of claim 3, wherein said movement disorder is related to NMDA-based excitotoxicity.

### Claim 9 (depends on 3)

The method of claim 3 comprising the further steps of:
selecting an agent that is a noncompetitive antagonist at NMDA receptors; and
administering said agent in conjunction with said acamprosate.

### Claim 10 (depends on 9)

The method of claim 9, wherein said agent is memantine or a derivative thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hyperkinesia comprises tardive dyskinesia.

### Claim 12

A method of treating tardive dyskinesia, comprising providing a patient suffering from tardive dyskinesia with an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.